Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II basket trial of rucaparib + atezolizumab in DNA repair-deficient or platinum-sensitive solid tumors
2018-001744-62Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rucaparib and atezolizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and prostate cancer (PCa), sponsored by Gustave Roussy. Primary endpoint: Overall Response Rate at 12 weeks. Started Aug 2018; status: completed.
02
Drugs
rucaparibatezolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)prostate cancer (PCa)
Beyond the preview
Go deeper on 2018-001744-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001744-62.